Chr. Hansen -- a global bioscience company, is entering a partnership with oral immunotherapy developer Prota Therapeutics for an innovative peanut allergy treatment.
The ambitious scientific project begins with Chr. Hansen's LGG probiotic strain and the researchers hope to enhance the formula by "bringing Prota Therapeutics' drug candidate, as one of two active pharmaceutical ingredients alongside LGG." The expectation is that the peanut allergy treatment will reach phase three in the clinical trial -- which is identified as "one of the first to involve a live microorganism." Chr. Hansen and Prota Therapeutics expect this trial to last about three years.
Although the investigation is focused on determining if probiotic treatment can have a soothing effect on peanut allergies, the researchers will potentially look into exploring its merits in collaboration with other foods.
Photo Credits: Shutterstock